Exemptia Dosage/Direction for Use

Exemptia needs to be administered as a subcutaneous injection.
Rheumatoid arthritis (RA): The recommended dose in adult patients is 40 mg every other week. Patients with RA not receiving methotrexate may benefit from increasing the frequency to 40 mg every week. Drugs such as methotrexate, glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during Adalimumab treatment.
Juvenile Idiopathic Arthritis: The recommended dose of Adalimumab for patients 2 years of age and older with polyarticular JIA is based on weight as shown as follows: See Table 4.

Click on icon to see table/diagram/image

Enthesitis related arthritis: The recommended dose is 24 mg/m² up to a maximum single dose of 40 mg administered every other week.
Psoriatic Arthritis: The recommended dose in adult patients is 40 mg every other week. Drugs such as methotrexate, glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during Adalimumab treatment.
Ankylosing Spondylitis (AS) and axial spondyloarthritis without radiographic evidence of AS: The recommended dose in adult patients is 40 mg every other week.
Crohn's disease: Adult patients and pediatric patients ≥40 kg: The recommended initial dose is 80 mg (Day 1) followed by 40 mg on Day 15, and further followed by 40 mg every other week.
For a more rapid response, an initial dose (Day 1) of 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15) can be used. Two weeks later (Day 29), begin a maintenance dose of 40 mg every other week.
Some patients who experience insufficient response may benefit from an increase in dosing frequency to 40 mg every week.
Pediatric patients <40 kg: The recommended initial dose is 40 mg (Day 1) followed by 20 mg on Day 15, and further followed by 20 mg every other week.
For a more rapid response, an initial dose (Day 1) of 80 mg (two 40 mg injections in one day), followed by 40 mg two weeks later (Day 15) can be used. Two weeks later (Day 29), begin a maintenance dose of 20 mg every other week.
Some patients who experience insufficient response may benefit from an increase in dosing frequency to 20 mg every week.
Ulcerative colitis: The recommended initial dose is 160 mg (Day 1) (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a maintenance dose of 40 mg every other week.
Some patients who experience insufficient response may benefit from an increase in dosing frequency to 40 mg every week.
Elderly patients: No dose adjustment is required.
Impaired renal and/or hepatic function: Adalimumab has not been studied in these patients. No dose recommendations can be made.